Clinical Lymphoma, Myeloma & Leukemia, Vol.20, Suppl.1 - September 2020

Session V: Multiple Myeloma Oral Abstract: MM-350 Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN Ajay K. Nooka 1 *, Jonathan L. Kaufman 1 , Cesar Rodriguez 2 , Andrzej Jakubowiak 3 , Leyla Shune 4 , Ashraf Badros 5 , Ajai Chari 6 , Paul G. Richardson 7 , Huiling Pei 8 , Jon Ukropec 9 , Jessica Vermeulen 10 , Daniela Hoehn 11 , Thomas S. Lin 11 , Peter M. Voorhees 12 1 Winship Cancer Institute, Emory University, Atlanta, GA, USA, 2 Wake Forest University School of Medicine, Winston-Salem, NC, USA, 3 University of Chicago Medical Center, Chicago, IL, USA, 4 Division of Hematologic Malignancies and Cellular Therapeutics (HMCT), University of Kansas Medical Center, Kansas City, MO, USA, 5 University of Maryland, Greenbaum Cancer Center, Baltimore, MD, USA, 6 Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA, 7 Dana-Farber Cancer Institute, Boston, MA, USA, 8 Janssen Research & Development, LLC, Titusville, NJ, USA, 9 Janssen Global Medical Affairs, Horsham, PA, USA, 10 Janssen Research & Development, LLC, Leiden, The Netherlands, 11 Janssen Scientific Affairs, LLC, Horsham, PA, USA, 12 Levine Cancer Institute, Atrium Health, Charlotte, NC, USA Session VI: Chronic Lymphocytic Leukemia Oral Abstract: CLL-091 Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results Paolo Ghia 1 *, Andrzej Pluta 2 , Malgorzata Wach 3 , Daniel Lysak 4 , Tomas Kozak 5 , Martin Simkovic 6 , Polina Kaplan 7 , Iryna Kraychok 8 , Arpad Illes 9 , Javier de la Serna 10 , Sean Dolan 11 , Philip Campbell 12 , Gerardo Musuraca 13 , Abraham Jacob 14 , Eric J. Avery 15 , Jae Hoon Lee 16 , Denise Wang 17 , Priti Patel 17 , Wojciech Jurczak 18 1 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy, 2 Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow, Poland, 3 Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland, 4 Fakultní Nemocnice Plzen, Pilsen, Czech Republic, 5 Fakultní Nemocnice Královske Vinohrady, Prague, Czech Republic, 6 University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic, 7 City Clinical Hospital No. 4DCC, Dnipro, Ukraine, 8 National Cancer Institute, Kiev, Ukraine, 9 University of Debrecen, Faculty of Medicine, Department of Hematology, Debrecen, Hungary, 10 Hospital Universitario 12de Octubre, Madrid, Spain, 11 Saint John Regional Hospital, University of New Brunswick, New Brunswick, Canada, 12 Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia, 13 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, 14 The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom, 15 Nebraska Hematology Oncology, Lincoln, NE, USA, 16 Gachon University Gil Medical Center, Incheon, Korea, Republic of (South), 17 Acerta Pharma, South San Francisco, CA, USA, 18 Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland Friday, September 11, 2020 Session VII: Hodgkin Lymphoma Oral Abstract: HL-323 Outcomes of First-Line Treatment in Patients with Advanced Clinical Stage Classic Hodgkin Lymphoma and Human Immunodeficiency Virus Infection Juan José Del Moral 1 *, Elena Tuna 1 , Antonio Olivas 2 , Alvaro Aguayo 1 , Gladys Agreda 1 1 Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 2 Division of Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City Session VIII: T-Cell Lymphoma Oral Abstract: TCL-127 Impact of Concomitant Steroids on Mogamulizumab Efficacy in MAVORIC Oleg Akilov 1 , Larisa Geskin 2 *, Takahiro Ito 3 , Karen Dwyer 3 , Fiona Herr 4 , Amy Musiek 5 1 University of Pittsburgh, Pittsburgh, PA, USA, 2 New York Presbyterian Hospital, New York, NY, USA, 3 Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ, USA, 4 Kyowa Kirin, Inc., Bedminster, NJ, USA, 5 Washington University School of Medicine, St. Louis, MO, USA Session IX: Indolent B-Cell Lymphoma Oral Abstract: IBCL-344 Marginal Zone Lymphoma: Epidemiology and Outcomes in a Mexican Center Rosana Córdova*, Rodrigo Castillo-Llanos, Ana Florencia Ramírez Instituto Nacional de Cancerología. Mexico City Session X: Aggressive B-Cell Lymphoma Oral Abstract: ABCL-256 Role of Radiotherapy Differs Between Stages for Primary Bone Large B-Cell Lymphoma in the Rituximab Era: A Real-World Study Shengling Ma 1 *, Yuanyuan Zhang 2 , Wei Shi 1 , Yu Hu 1 1 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China